Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: Same prognosis in a large randomized trial

International Journal of Gynecological Cancer

Volumn 19, Issue 1, 2009, Pages 88-93

  Timmers, P J ^a   Zwinderman, A H ^b   Teodorovic, I ^c   Vergote, I ^d   Trimbos, J B ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Data Center   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clear cell carcinoma; Early ovarian neoplasm; Serous adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RUPTURE; SALPINGOOOPHORECTOMY; TREATMENT RESPONSE; TUMOR RECURRENCE; ADENOCARCINOMA; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CYSTADENOCARCINOMA; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADENOCARCINOMA, CLEAR CELL; ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 65649113602     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181991546     Document Type: Article

References (39)

1. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60:412-417.
2. Montag AG, Jenison EL, Griffiths CT, et al. Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int J Gynecol Pathol. 1989;8(2):85-96.
3. Czernobilsky B, Silverman BB, Enterline HT. Clear cell carcinoma of the ovary. A clinico-pathologic analysis of pure and mixed forms and comparison with endometrioid carcinoma. Cancer. 1970;25:762-772.
4. Schiller W. Mesonephroma ovarii. Am J Cancer. 1939;35:1-21.
5. Saphir O, Lackner JE. Adenocarcinoma with clear cells (hypernephroid) of ovary. Surg Gynecolog Obstet. 1944;79:539-543.
6. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumours. In International Histological Classification of Tumours, no 9. Geneva: World Health Organization, 1973:17-54.
7. Kennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989;32:342-349.
8. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989;32:65-71.
9. Yoonessi M, Weldon D, Satchidand SK, et al. Clear cell ovarian adenocarcinoma. J Surg Oncol. 1984;27:289-297.
10. O'Brien ME, Schofield JB, Tan S, et al. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol. 1993;49:250-254.
11. Crozier MA, Copeland LJ, Silva EG, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989;35:199-203.
12. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998;70: 255-258.
13. Kita T, Kikuchi Y, Kudoh K, et al. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep. 2000;7:327-331.
14. Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Gynecol. 1971;37:860-867.
15. Brescia RJ, Dubin N, Demopoulos RI. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. Int J Gynecol Path. 1989;8:132-138.
16. Gorai I, Nakazawa T, Miyagi E, et al. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol Oncol. 1995;57(1):33-46.
17. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma. European Organisation for Research and Treatment of Cancer. Adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst. 2003;95:113-124.
18. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm Trial I and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: two parallel randomised phase III trials of adjuvant chemotherapy in patients with early stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105-112.
19. Trimbos JB, Timmers P. Chemotherapy for early ovarian cancer. Curr Opin Obstet Gynecol. 2004;16:43-48.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos. 1958;53:457-481.
21. Doshi N, Tobon H. Primary clear cell carcinoma of the ovary. An analysis of 15 cases and a review of the literature. Cancer. 1977;39: 2658-2664.
22. Fine G, Clarke HD, Horn RC. Mesonephroma of the ovary. A clinical, morphological, and histogenic appraisal. Cancer. 1973;31:398-410.
23. Russel P. The pathologic assessment of ovarian neoplasms. Introduction to the common Bepithelial[ tumors and analysis of benign Bepithelial[ tumors. Pathology. 1979;11:5-26.
24. Ohkawa D, Amasaki H, Terashima Y, et al. Clear cell carcinoma of the ovary. Light and electron microscopic studies. Cancer. 1977;40:3019-3029.
25. Shevchuk MM, Monsanto BW, Fenoglio CM, et al. Clear cell carcinoma of the ovary: a clinicopathologic study with review of the literature. Cancer. 1981;47:1344-1351.
26. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand. 1971;50:1-7.
27. Benda JA, Zaino R. GOG Pathology Manual. Buffalo, NY: Gynecologic Oncology Group, 1994.
28. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19:7-15.
29. Hreshchyshyn MM, Park RC, Blessing JA, et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol Oncol. 1980; 138:139-145.
30. Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100(2):281-287.
31. Tammela J, Geisler JP, Eskew PN Jr, et al. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaec Oncol. 1998;19:438-440.
32. Rubin SC, Wang GY, Curtin JP, et al. Platinum-based chemotherapy of high risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynaecol. 1993;82:143-147.
33. Zanetta G, Rota S, Chiari S, et al. The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma. Ann Oncol. 1998;9:1097-1101.
34. Vergote I, De Brabander J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176-182.
35. Ahmed FY, Wiltshaw E, A'Hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol. 1996; 14:2968-2975.
36. Norris HJ, Robinowitz M. Ovarian adenocarcinoma of mesonephric type. Cancer. 1971;28:1074-1081.
37. Recio FO, Piver MS, Hempling RE, et al. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer. 1996;78:2157-2163.
38. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer. 2000;88:2584-2589.
39. Swenerton KD, Hilsop TG, Spinelli J, et al. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol. 1985; 65:264-270.